Search clinical trials for: moderate to severe allergic asthma

Total 475535 results

The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE) (ESSENCE)

Moderate to Severe Allergic Asthma

China
Gelb, Arthur F., M.D.

Recruiting

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Asthma

United States
Eli Lilly and Company
Dermira, Inc.

Active, not recruiting

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

Atopic Dermatitis

United States, Spain, Canada, France, Korea, Republic of, Taiwan, Australia, Germany, Bulgaria, Estonia, Latvia, Lithuania, Mexico, Poland, Singapore, Ukraine
Organon and Co

Completed

An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma

Asthma | Allergic Rhinitis
Jemincare

Completed

Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

Healthy

China
Cinnagen

Completed

Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Allergic Asthma | Uncontrolled Moderate to Severe

Iran, Islamic Republic of
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Genentech, Inc.

Terminated

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma (EDURO)

Moderate-to-severe Allergic Asthma

United States
Novartis Pharmaceuticals

Completed

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium (ARGON)

Asthma

Germany, India, Israel, Poland, Argentina, Russian Federation, Greece, Serbia, Turkey, Hungary, Mexico, Peru, Slovakia, Czechia, South Africa, Taiwan, Vietnam, Spain, Colombia, Chile
GlaxoSmithKline

Terminated

Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

Asthma

France, Netherlands, Russian Federation, United Kingdom
Shiraz University of Medical Sciences

Unknown

Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis

Allergic Rhinitis

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Asthma

United States, Canada, Russian Federation, Mexico, Australia, Ukraine
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Asthma

China
Novartis Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Poland, Romania, Croatia, Estonia, Netherlands, Slovakia, Latvia, Lithuania, United Kingdom, Argentina, Bulgaria, Serbia, Austria, Hungary, Spain, Greece, Canada, Denmark, Czechia
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
Henan University of Traditional Chinese Medicine
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Pulmonary Disease, Chronic Obstructive

China
Mundipharma Research Limited

Completed

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Asthma Bronchiale

United Kingdom
Mundipharma Research Limited

Completed

An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma

Asthma Bronchiale

Poland, Romania, Netherlands, United Kingdom, Germany, Hungary
Mundipharma Research Limited

Completed

Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients

Asthma

Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, India, Poland, Romania
Children's Hospital of The King's Daughters
Novartis; Genentech, Inc.

Completed

A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

ALLERGIC ASTHMA
GlaxoSmithKline

Completed

A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.

Asthma

Czechia, Slovakia
GlaxoSmithKline

Completed

Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 mcg/Dose and Salmeterol 50 mcg/Dose - ADERE PROJECT (ADERE (Ped))

Asthma
Sanofi
Regeneron Pharmaceuticals

Completed

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Asthma

Spain, United States, Chile, Australia, France, Mexico, Argentina, Italy, Japan, Poland, Russian Federation, South Africa, Turkey, Ukraine, Korea, Republic of, New Zealand
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
Genentech, Inc.

Completed

A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma

Asthma
Johann Wolfgang Goethe University Hospital

Withdrawn

The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children (BHR)

Allergy | Allergic Asthma | Intrinsic Asthma | Bronchial Hyperresponsiveness

Germany
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

Chronic Obstructive Pulmonary Disease | COPD
AstraZeneca

Completed

Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)

Asthma

United Kingdom, Switzerland, Belgium, France, Italy, Spain, Netherlands
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Novartis Pharmaceuticals
Genentech, Inc.

Completed

Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy

Persistent Allergic Asthma

China
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
Genentech, Inc.

Completed

A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

Asthma
Merck KGaA, Darmstadt, Germany

Terminated

Raptiva in Palm and Sole Psoriasis

Chronic Plaque Psoriasis
Creighton University
Novartis Pharmaceuticals

Completed

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Lung Disease

United States
Genentech, Inc.

Completed

An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g

Asthma
Novartis Pharmaceuticals
Genentech, Inc.

Completed

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists (eXplore)

Allergic Asthma

United States, Sweden, United Kingdom, France, Canada, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Asthma

United States
DiMango, Emily, M.D.
Novartis; Genentech, Inc.

Completed

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

Asthma

United States
Genentech, Inc.

Completed

A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)

Asthma
Novartis
Genentech, Inc.

Completed

Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients

Asthma
Novartis
Daiichi Sankyo Co., Ltd.

Completed

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Asthma

Japan
Novartis
Daiichi Sankyo Co., Ltd.

Completed

Study of Omalizumab in Moderate to Severe Bronchial Asthma

Asthma
Novartis

Completed

Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

Chronic Urticaria

Germany
Novartis

Completed

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Germany, United States, Belgium, Hungary
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Asthma

United States, Puerto Rico
SkyePharma AG
Abbott

Completed

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

Asthma

United States, Ukraine, Mexico, Peru, Romania
Novartis Pharmaceuticals
Genentech, Inc.

Completed

Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Puerto Rico
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Asthma

United Kingdom, Germany, Hungary, Poland, Romania
SkyePharma AG
Abbott; MDS Pharma Services

Completed

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

Asthma

United States, Chile, Mexico, Peru, Romania, Hungary, South Africa, Ukraine, Poland, Argentina
Children's Hospital of Philadelphia
Novartis Pharmaceuticals

Completed

Combination Therapy for Atopic Dermatitis

Atopic Dermatitis

United States

3

Subscribe